NCT05054218 is a clinical trial of mRNA-1273 in Covid19, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Who is sponsoring NCT05054218?

NCT05054218 is sponsored by H. Lee Moffitt Cancer Center and Research Institute.

What drugs are being tested in NCT05054218?

Interventions in NCT05054218: mRNA-1273.

What condition does NCT05054218 study?

NCT05054218 studies Covid19, SARS-CoV2 Infection.

Is NCT05054218 still recruiting?

NCT05054218 is currently completed. Last updated 14 April 2023.

Last reviewed 2023-04-14 · How we verify

NCT05054218

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

Completed Last updated 14 April 2023

What this trial tests

trial testing mRNA-1273 in Covid19 in 336 participants. Completed in 29 August 2022.

Timeline

10 September 2021

Primary endpoint
16 July 2022

29 August 2022

Quick facts

Lead sponsor	H. Lee Moffitt Cancer Center and Research Institute
Status	Completed
Study type	OBSERVATIONAL
Enrollment	336
Start date	10 September 2021
Primary completion	16 July 2022
Estimated completion	29 August 2022
Sites	1 location across United States

Drugs / interventions tested

mRNA-1273 — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →
SARS-CoV2 Infection — all drugs for SARS-CoV2 Infection →

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Who can join

18 and older, any sex, with Covid19 or SARS-CoV2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigators will evaluate the immunogenicity of a third dose of mRNA-1273 SARS-CoV-2 vaccine among cancer patients receiving the recommended third vaccine dose

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!
Chavda VP, Jogi G, Dave S, Patel BM, et al · · 2023 · cited 15× · PMID 36992091 · DOI 10.3390/vaccines11030507
Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients.
Dukes CW, Potez M, Lancet J, Kuter BJ, et al · · 2023 · cited 2× · PMID 38250826 · DOI 10.3390/vaccines12010013

Verify or expand the search:

Other trials of mRNA-1273

Trials testing the same drug.

NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
NCT06113692 — A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine · completed
NCT05345873 — A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Populat · Phase 2 · unknown
NCT05397223 — A Study of Modified mRNA Vaccines in Healthy Adults · Phase 1 · completed
NCT05375838 — A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Ol · Phase 1, PHASE2 · completed

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other H. Lee Moffitt Cancer Center and Research Institute trials

Trials by the same sponsor.

NCT05041335 — Wet Heparinized Suction for Abdominal Cancer · NA · not yet recruiting
NCT07222995 — Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs · NA · recruiting
NCT06047977 — Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors · Phase 1 · recruiting
NCT06121180 — Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma · Phase 2 · recruiting
NCT06193486 — Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05054218 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute
Last refreshed: 14 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05054218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing